Evelo Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 66
- Market Cap
- -
- Website
- http://www.evelobio.com
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Evaluation of the Immunopharmacology of EDP1815 and EDP2939
- Conditions
- KLH and Imiquimod Induced Skin Inflammation in Healthy Volunteers
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Evelo Biosciences, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05682222
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Evelo Biosciences, Inc.
- Target Recruit Count
- 287
- Registration Number
- NCT05439941
- Locations
- 🇺🇸
USA-131, Birmingham, Alabama, United States
🇺🇸USA 112, Fountain Valley, California, United States
🇺🇸USA 123, Fremont, California, United States
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Evelo Biosciences, Inc.
- Target Recruit Count
- 421
- Registration Number
- NCT05121480
- Locations
- 🇺🇸
USA-131, Birmingham, Alabama, United States
🇺🇸USA-112, Fountain Valley, California, United States
🇺🇸USA-123, Fremont, California, United States
Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms
- Conditions
- DisintegrationHealthy
- Interventions
- Drug: EDP1815 capsule ADrug: EDP1815 capsule BDrug: EDP1815 tablet
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Evelo Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05066373
- Locations
- 🇬🇧
BDD Pharma Ltd, Glasgow, Scotland, United Kingdom
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Evelo Biosciences, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04927195
- Locations
- 🇬🇧
MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom
🇬🇧Medicines Evaluation Unit (MEU), Manchester, Greater Manchester, United Kingdom
🇬🇧MAC Clinical Research, Leeds, West Yorkshire, United Kingdom
- Prev
- 1
- 2
- Next